Myocardial ischemia is difficult to diagnose effectively with still few well-defined biochemical
markers for identification in advance, or in the absence of myocardial necrosis.“Ischemia …

Myocardial ischemia has become the leading cause of mortality in western countries and
this unfavorable trend is unlikely to reverse in the near future. The events progression …

Albumin is one of the most abundant proteins in the body of mammals: about 40% of its pool
is located in the intravascular space and the remainder is found in the interstitial space. The …

First identified in the early 1990s, IMA is produced when ischemia stresses released from
hypoxic heart tissue induce modification of circulating albumin. 5, 6 The amino terminal end …

Myocardial ischemia (MI) induces many changes in the body, including pH decrease and
electrolyte imbalance. No obvious symptoms of MI appear until irreversible cellular injuries …

Publisher Summary The chapter presents a general overview of the clinical and analytical
issues pertaining to the albumin–cobalt binding (ACB) test that measures ischemia-modified …

Background Ischemia-modified albumin (IMA) has been shown to be a rapidly rising and
sensitive biochemical marker especially for the diagnosis of myocardial ischemia. The aim of …

Ischemia modified albumin (IMA), as measured using the albumin cobalt binding test, is
currently the most promising biomarker for early detection of ischemia before the onset of …

The biomarker “ischemia-modified albumin”(IMA), measured by the albumin–cobalt-binding
assay (ACB assay), is the only FDA-approved biomarker for early diagnosis of myocardial …

OBJECTIVES:: There is concern that ischemia-modified albumin (IMA) levels measured by
albumin cobalt binding (ACB) assay reflect mainly albumin concentrations rather than …